{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23","upperLimit":"216","value":"24.3"},{"groupId":"OG001","lowerLimit":"12","upperLimit":"53","value":"24.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"Time to CCyR was defined as the time from the date of randomization to the date of the first documented CCyR.","dispersionType":"Full Range","groups":[{"description":"Participants randomized to asciminib 40mg BID","id":"OG000","title":"Asciminib"},{"description":"Participants randomized to bosutinib 500mg QD","id":"OG001","title":"Bosutinib"}],"paramType":"MEDIAN","populationDescription":"CCyR responder set was a subset of FAS and included patients who did not have CCyR at baseline and achieved CCyR at any time on randomized treatment. FAS comprised of all randomized participants.","reportingStatus":"POSTED","timeFrame":"216 Weeks","title":"Time to Complete Cytogenetic Response Rate (CCyR) Among Participants Who Achieved CCyR","type":"SECONDARY","unitOfMeasure":"Weeks"}